DOP2004000994A - Derivados de indano heterociclicos sustituidos y compuestos relacionados para el tratamiento de la esquizofrenia. - Google Patents
Derivados de indano heterociclicos sustituidos y compuestos relacionados para el tratamiento de la esquizofrenia.Info
- Publication number
- DOP2004000994A DOP2004000994A DO2004P000994A DO2004000994A DOP2004000994A DO P2004000994 A DOP2004000994 A DO P2004000994A DO 2004P000994 A DO2004P000994 A DO 2004P000994A DO 2004000994 A DO2004000994 A DO 2004000994A DO P2004000994 A DOP2004000994 A DO P2004000994A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- azithromycin
- oral
- azitromycin
- effective amount
- dosage form
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
Abstract
UNA FORMA DE DOSIFICACION ORAL QUE COMPRENDE AZITROMICINA Y UNA CANTIDAD EFICAZ DE UN AGENTE ALCALINIZANTE. PREFERIBLEMENTE, DICHA FORMA DE DOSIFICACION ORAL COMPRENDE UNA CANTIDAD EFICAZ DE UN AGENTE ALCALIRIIZANTE Y UN MULTIPARTICULADO DE AZITROMICINA EN EL QUE DICHO MULTIPARTICULADO COMPRENDE AZITROMICINA, UNA MEZCLA DE MONOBEHENATO DE GLICERILO, DIBEHENATO DE GLICERILO Y TRIBEHENATO DE GLICERHO Y UN POLOXAMERO. TIPICAMENTE, LA FORMA DE DOSIFICACION ORAL INCLUYE CUALQUIER MEDIO DE ADMINISTRACION ORAL ADECUADO TAL COMO UN POLVO PARA SUSPENSION ORAL, UN ENVASE O SOBRECITO DE DOSIS UNITARIA, UN COMPRIMIDO O UNA CAPSULA. EMAS SE DESCRIBE UNA SUSPENSION ORAL QUE COMPRENDE AZITROMICINA, UNA CANTIDAD EFICAZ DE UN AGENTE ALCALINIZANTE Y UN VEHICULO. PREFERIBLEMENTE, LA AZITROMICINA ESTA EN FORMA MUITIPARTICULADA EN LA QUE DICHO MULTIPARTICULADO COMPRENDE AZITROMICINA, UNA MEZCLA DE MONOBEHENATO DE GLICERILO, DIBEHENATO DE GLICERILO Y TRIBEHENATO DE GLICERILO Y UN POLOXAMERO. MBIÉN SE DESCRIBE UN PROCEDIMIENTO PARA REDUCIR LOS EFECTOS SECUNDARIOS GASTROINTESTINALES ASOCIADOS A LA ADMINISTRACION DE AZITROMICINA A UN MAMIFERO, QUE COMPRENDE LA ADMINISTRACION DE FORMA CONTIGUA DE AZITROMICINA Y UNA CANTIDAD EFICAZ DE UN AGENTE ALCALINIZANTE A DICHO MAMIFERO EN EL QUE LA FRECUENCIA DE EFECTOS SECUNDARIOS GASTROINTESTINALES ES MENOR QUE LA QUE SE EXPERIMENTA ADMINISTRANDO UNA DOSIS IGUAL DE AZITROMICINA SIN DICHO AGENTE ALCALINIZANTE. ADEMAS SE DESCRIBE UN PROCEDIMIENTO PARA TRATAR UNA INFECCION BACTERIANA O PROTOZOARIA EN UN MAMÍFERO QUE LO NECESITE QUE COMPRENDE LA MINISTRACIÓN DE FORMA CONTIGUA A DICHO MAMÍFERO DE UNA DOSIS ÚNICA DE UNA FORMA DE DOSIFICACIÓN ORAL EN LA QUE DICHA FORMA DE DOSIFICACIÓN ORAL COMPRENDE AZITROMICINA Y UNA CANTIDAD EFICAZ DE UN AGENTE ALCALINIZANTE. ICIONALMENTE SE DESCRIBEN MULTIPARTICULADOS DE AZITROMICINA QUE COMPRENDEN AZITROMICINA, UN TENSIOACTIVO; Y UN VEHÍCULO FARMACÉUTICAMENTE ACEPTABLE.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52708403P | 2003-12-04 | 2003-12-04 | |
US10/763,340 US6984403B2 (en) | 2003-12-04 | 2004-01-23 | Azithromycin dosage forms with reduced side effects |
Publications (1)
Publication Number | Publication Date |
---|---|
DOP2004000994A true DOP2004000994A (es) | 2005-06-30 |
Family
ID=34468055
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DO2004P000994A DOP2004000994A (es) | 2003-12-04 | 2004-09-09 | Derivados de indano heterociclicos sustituidos y compuestos relacionados para el tratamiento de la esquizofrenia. |
Country Status (36)
Country | Link |
---|---|
US (4) | US6984403B2 (es) |
EP (1) | EP1537859B1 (es) |
JP (2) | JP4602711B2 (es) |
KR (1) | KR100906290B1 (es) |
AR (1) | AR045630A1 (es) |
AT (1) | ATE407663T1 (es) |
BR (1) | BRPI0403935B8 (es) |
CA (1) | CA2467611C (es) |
CL (1) | CL2004001501A1 (es) |
CR (1) | CR7500A (es) |
CY (1) | CY1108486T1 (es) |
DE (1) | DE602004016444D1 (es) |
DK (1) | DK1537859T3 (es) |
DO (1) | DOP2004000994A (es) |
EA (1) | EA010110B1 (es) |
ES (1) | ES2312929T3 (es) |
GE (1) | GEP20074056B (es) |
HK (1) | HK1080367B (es) |
HR (1) | HRP20040865A2 (es) |
IL (1) | IL164165A (es) |
IS (1) | IS2672B (es) |
MA (1) | MA27848A1 (es) |
MX (1) | MXPA04009424A (es) |
NL (1) | NL1026315C2 (es) |
NO (1) | NO20043903L (es) |
NZ (1) | NZ535464A (es) |
OA (1) | OA12858A (es) |
PA (1) | PA8611501A1 (es) |
PE (1) | PE20050573A1 (es) |
PL (2) | PL1537859T3 (es) |
PT (1) | PT1537859E (es) |
RS (1) | RS84704A (es) |
SI (1) | SI1537859T1 (es) |
TW (1) | TWI351969B (es) |
UY (1) | UY28509A1 (es) |
WO (1) | WO2005053650A1 (es) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL179910B1 (pl) † | 1994-05-06 | 2000-11-30 | Pfizer | Postac dawkowania o kontrolowanym uwalnianiu zawierajaca azytromycyne PL PL PL PL PL PL PL PL |
US20030158220A1 (en) * | 1997-11-03 | 2003-08-21 | Foss Joseph F. | Use of methylnaltrexone and related compounds to treat chronic opioid use side effects |
PT2368553E (pt) * | 2003-04-08 | 2015-03-03 | Progenics Pharm Inc | Formulações farmacêuticas contendo metilnaltrexona |
PT1691787E (pt) * | 2003-12-04 | 2008-09-02 | Pfizer Prod Inc | Método de formação de multipartículas farmacêuticas |
WO2005053652A1 (en) * | 2003-12-04 | 2005-06-16 | Pfizer Products Inc. | Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride |
US8236349B2 (en) * | 2004-04-12 | 2012-08-07 | Bend Research Inc. | Taste-masked drugs in rupturing multiparticulates |
LT1765292T (lt) | 2004-06-12 | 2018-01-10 | Collegium Pharmaceutical, Inc. | Nuo piktnaudžiavimo apsaugotos vaistų formos |
JP3933683B2 (ja) | 2004-07-02 | 2007-06-20 | わかもと製薬株式会社 | アジスロマイシン含有水性医薬組成物及びその調製方法 |
JP4713104B2 (ja) * | 2004-08-04 | 2011-06-29 | ファイザー株式会社 | アジスロマイシン類を有効成分とする苦味が抑制された安定な組成物 |
US20060193908A1 (en) * | 2004-11-09 | 2006-08-31 | Burnside Beth A | Extended release formulations of poorly soluble antibiotics |
CN104248763A (zh) * | 2005-03-07 | 2014-12-31 | 芝加哥大学 | 阿片样物质拮抗剂用于减少内皮细胞增殖和迁移的用途 |
US8524731B2 (en) * | 2005-03-07 | 2013-09-03 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
US8518962B2 (en) | 2005-03-07 | 2013-08-27 | The University Of Chicago | Use of opioid antagonists |
US9662325B2 (en) | 2005-03-07 | 2017-05-30 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
US20060252831A1 (en) * | 2005-05-06 | 2006-11-09 | Christopher Offen | Method for the treatment of magnesium and potassium deficiencies |
US20060252830A1 (en) * | 2005-05-06 | 2006-11-09 | Brandon Stephen F | Method for the treatment of magnesium and potassium deficiencies |
AR057325A1 (es) * | 2005-05-25 | 2007-11-28 | Progenics Pharm Inc | Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos |
AR057035A1 (es) * | 2005-05-25 | 2007-11-14 | Progenics Pharm Inc | SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS |
SG2014009252A (en) * | 2005-12-22 | 2014-05-29 | Otsuka Pharma Co Ltd | Method of producing drug-containing wax matrix particles, extruder to be used in the method and sustained-release preparation containing cilostazol |
CN101340882B (zh) * | 2005-12-22 | 2015-02-11 | 大塚制药株式会社 | 含有药物的蜡基质粒子的制造方法、用于该方法的挤出机、及含有西洛他唑的缓释制剂 |
WO2007143507A2 (en) * | 2006-06-05 | 2007-12-13 | Auspex Pharmaceuticals, Inc. | Preparation and utility of substituted erythromycin analogs |
TW200817048A (en) * | 2006-09-08 | 2008-04-16 | Wyeth Corp | Dry powder compound formulations and uses thereof |
US10357462B2 (en) * | 2006-11-30 | 2019-07-23 | Ben Research, Inc. | Multiparticulates of spray-coated drug and polymer on a meltable core |
US11116728B2 (en) | 2006-11-30 | 2021-09-14 | Bend Research, Inc. | Multiparticulates of spray-coated drug and polymer on a meltable core |
JP5162134B2 (ja) * | 2007-01-22 | 2013-03-13 | 愛媛県 | 機能性材料の製造方法、機能性材料、シート状構造体、及び衛生製品 |
ES2350029T3 (es) * | 2007-03-02 | 2011-01-17 | Farnam Companies, Inc. | Pellets de liberación sostenida que comprenden un material tipo cera. |
EP2139890B1 (en) | 2007-03-29 | 2014-06-25 | Wyeth LLC | Peripheral opioid receptor antagonists and uses thereof |
CA2865389A1 (en) * | 2007-03-29 | 2008-10-09 | Progenics Pharmaceuticals, Inc. | Crystal forms and uses thereof |
PE20090700A1 (es) * | 2007-03-29 | 2009-07-13 | Progenics Pharm Inc | Compuestos heterociclicos como antagonistas del receptor opioide periferico |
DE102007026550A1 (de) * | 2007-06-08 | 2008-12-11 | Bayer Healthcare Ag | Extrudate mit verbesserter Geschmacksmaskierung |
DE102007034155A1 (de) * | 2007-07-21 | 2009-01-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Vorrichtung mit mindestens einer Verpackungseinheit mit einem zur Radiofrequenz-Identifikation dienenden RFID-Chip und Verfahren dazu |
CA2711807A1 (en) | 2008-01-08 | 2009-07-16 | Akthelia Pharmaceuticals | Agonists for antimicrobial peptide systems |
CN101959892B (zh) | 2008-02-06 | 2014-01-08 | 普罗热尼奇制药公司 | (r),(r)-2,2’-二-甲基纳曲酮的制备和用途 |
JP5647098B2 (ja) | 2008-03-21 | 2014-12-24 | ザ ユニヴァーシティー オヴ シカゴ | オピオイド拮抗薬とmTOR阻害薬を用いた治療 |
RU2495662C2 (ru) * | 2008-07-21 | 2013-10-20 | Отономи, Инк. | Антимикробные композиции с контролируемым высвобождением для лечения ушных заболеваний |
CA2676881C (en) | 2008-09-30 | 2017-04-25 | Wyeth | Peripheral opioid receptor antagonists and uses thereof |
US8106111B2 (en) | 2009-05-15 | 2012-01-31 | Eastman Chemical Company | Antimicrobial effect of cycloaliphatic diol antimicrobial agents in coating compositions |
EP2314286A1 (de) * | 2009-10-21 | 2011-04-27 | Ratiopharm GmbH | Schmelzgranuliertes Cinacalcet |
US10668060B2 (en) | 2009-12-10 | 2020-06-02 | Collegium Pharmaceutical, Inc. | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
WO2011125075A2 (en) | 2010-04-08 | 2011-10-13 | Fdc Limited | A novel gastroretentive delivery of macrolide |
LT2673237T (lt) | 2011-02-11 | 2019-05-10 | Zs Pharma, Inc | Cirkonio silikato panaudojimas hiperkalemijos gydymui |
JP6038128B2 (ja) | 2011-06-03 | 2016-12-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー |
WO2013088274A1 (en) | 2011-12-14 | 2013-06-20 | Wockhardt Limited | Anhydrous amorphous azithromycin composition free of azithromycin dihydrate |
US9943637B2 (en) | 2012-06-11 | 2018-04-17 | ZS Pharma, Inc. | Microporous zirconium silicate and its method of production |
EP2872148A4 (en) | 2012-07-11 | 2016-06-15 | Zs Pharma Inc | MICROPOROUS ZIRCONESILICATE FOR THE TREATMENT OF HYPERCALMYME IN HYPERCALCEAN PATIENTS AND IMPROVED CALCIUM-CONTAINING COMPOSITIONS FOR THE TREATMENT OF HYPERKALEMIA |
CA2891053C (en) | 2012-10-22 | 2020-12-01 | ZS Pharma, Inc. | Microporous zirconium silicate for treating hyperkalemia |
US10695365B2 (en) | 2012-10-22 | 2020-06-30 | ZS Pharma, Inc. | Microporous zirconium silicate for the treatment of hyperkalemia |
CA2933048A1 (en) * | 2013-12-10 | 2015-06-18 | ZS Pharma, Inc. | Zirconium silicate for treating hyperkalemia without co-administering lithium |
EP3825305A1 (en) | 2014-08-28 | 2021-05-26 | Eisai R&D Management Co., Ltd. | Process for preparing lenvatinib |
PT3263106T (pt) | 2015-02-25 | 2024-01-12 | Eisai R&D Man Co Ltd | Método para suprimir o amargor do derivado de quinolina |
AU2016229111A1 (en) * | 2015-03-10 | 2017-09-21 | Lumos Pharma, Inc. | Cyclocreatine microsuspension |
ES2882578T3 (es) | 2015-06-10 | 2021-12-02 | Piedmont Animal Health Llc | Formulaciones antibióticas inyectables y uso de las mismas |
KR20180018695A (ko) | 2015-06-16 | 2018-02-21 | 가부시키가이샤 프리즘 파마 | 항암제 |
KR20190008840A (ko) | 2016-03-15 | 2019-01-25 | 에이서 테라퓨틱스 인크. | 소듐 페닐부티레이트를 포함하는 맛우수한 조성물 및 그의 용도 |
WO2017222575A1 (en) | 2016-06-23 | 2017-12-28 | Collegium Pharmaceutical, Inc. | Process of making more stable abuse-deterrent oral formulations |
EP3576755A4 (en) * | 2017-02-02 | 2020-12-02 | McMaster University | BICARBONATE AS A POTENTIATOR FOR ANTIMICROBIAL INGREDIENTS |
WO2020024060A1 (en) | 2018-08-01 | 2020-02-06 | Mcmaster University | Methods for inhibiting microbe growth |
CN111643455A (zh) * | 2020-06-22 | 2020-09-11 | 健民药业集团股份有限公司 | 一种阿奇霉素缓释干混悬剂及其制备方法 |
WO2022220669A1 (es) * | 2021-04-16 | 2022-10-20 | Garcia Perez Miguel Angel | Combinación sólida oral para el tratamiento de infección por virus |
CN114699386B (zh) * | 2022-04-14 | 2023-05-23 | 深圳职业技术学院 | 阿奇霉素组合物及其制备方法 |
Family Cites Families (130)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US190365A (en) * | 1877-05-01 | Improvement in running-gear for vehicles | ||
US25342A (en) * | 1859-09-06 | Justus k | ||
US26851A (en) * | 1860-01-17 | Improvement | ||
US228357A (en) * | 1880-06-01 | Walter m | ||
US3590A (en) * | 1844-05-17 | Rule or measure | ||
US165563A (en) * | 1875-07-13 | Improvement in snow-plows | ||
US14951A (en) * | 1856-05-27 | Boot-tree | ||
US6650A (en) * | 1849-08-14 | Edmund blunt | ||
US2955956A (en) * | 1957-05-15 | 1960-10-11 | Morton Salt Co | Process and apparatus for coating granules |
US4086346A (en) * | 1974-04-06 | 1978-04-25 | Bayer Aktiengesellschaft | Preparation of melt-sprayed spherical phenacetin granules |
US4092089A (en) * | 1974-04-06 | 1978-05-30 | Bayer Aktiengesellschaft | Apparatus for the preparation of melt-sprayed spherical phenacetin granules |
US4053264A (en) * | 1976-01-30 | 1977-10-11 | United Technologies Corporation | Apparatus for making metal powder |
US4293570A (en) * | 1979-04-02 | 1981-10-06 | Chimicasa Gmbh | Process for the preparation of sweetener containing product |
YU43006B (en) * | 1981-03-06 | 1989-02-28 | Pliva Pharm & Chem Works | Process for preparing n-methyl-11-aza-10-deoxo-10-dihydro erythromycin and derivatives thereof |
US4474768A (en) * | 1982-07-19 | 1984-10-02 | Pfizer Inc. | N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor |
US4675140A (en) * | 1984-05-18 | 1987-06-23 | Washington University Technology Associates | Method for coating particles or liquid droplets |
US4874611A (en) | 1985-06-20 | 1989-10-17 | The Dow Chemical Company | Microencapsulated ant bait |
US5100592A (en) * | 1986-03-12 | 1992-03-31 | Washington University Technology Associated, Inc. | Method and apparatus for granulation and granulated product |
US5019302A (en) * | 1986-03-12 | 1991-05-28 | Washington University Technology Associates, Inc. | Method for granulation |
US5456932A (en) | 1987-04-20 | 1995-10-10 | Fuisz Technologies Ltd. | Method of converting a feedstock to a shearform product and product thereof |
US5236734A (en) * | 1987-04-20 | 1993-08-17 | Fuisz Technologies Ltd. | Method of preparing a proteinaceous food product containing a melt spun oleaginous matrix |
US5387431A (en) * | 1991-10-25 | 1995-02-07 | Fuisz Technologies Ltd. | Saccharide-based matrix |
UA27040C2 (uk) * | 1987-07-09 | 2000-02-28 | Пфайзер Інк. | Кристалічhий дигідрат азитроміциhу та спосіб одержаhhя кристалічhого дигідрату азитроміциhу |
WO1989002271A1 (en) | 1987-09-10 | 1989-03-23 | Pfizer | Azithromycin and derivatives as antiprotozoal agents |
HRP20020231A2 (en) * | 2002-03-18 | 2003-12-31 | Pliva D D | ISOSTRUCTURAL PSEUDOPOLYMORPHS OF 9-DEOXO-9a-AZA-9a-METHYL-9a-HOMOERYTHROMYCIN A |
DE3812567A1 (de) * | 1988-04-15 | 1989-10-26 | Basf Ag | Verfahren zur herstellung pharmazeutischer mischungen |
US5064650A (en) | 1988-04-19 | 1991-11-12 | Southwest Research Institute | Controlled-release salt sensitive capsule for oral use and adhesive system |
US5024842A (en) * | 1988-04-28 | 1991-06-18 | Alza Corporation | Annealed coats |
US5160743A (en) | 1988-04-28 | 1992-11-03 | Alza Corporation | Annealed composition for pharmaceutically acceptable drug |
US4931285A (en) * | 1988-04-28 | 1990-06-05 | Alza Corporation | Aqueous based pharmaceutical coating composition for dosage forms |
US5047244A (en) * | 1988-06-03 | 1991-09-10 | Watson Laboratories, Inc. | Mucoadhesive carrier for delivery of therapeutical agent |
US5169645A (en) | 1989-10-31 | 1992-12-08 | Duquesne University Of The Holy Ghost | Directly compressible granules having improved flow properties |
JPH03206039A (ja) * | 1990-01-08 | 1991-09-09 | Kyoto Yakuhin Kogyo Kk | ニフェジピン持続性製剤 |
US5084287A (en) * | 1990-03-15 | 1992-01-28 | Warner-Lambert Company | Pharmaceutically useful micropellets with a drug-coated core and controlled-release polymeric coat |
US5213810A (en) * | 1990-03-30 | 1993-05-25 | American Cyanamid Company | Stable compositions for parenteral administration and method of making same |
DE69111287T2 (de) * | 1990-04-18 | 1995-12-21 | Asahi Chemical Ind | Kugelförmige Keimkerne, kugelförmige Granulate sowie Verfahren zu deren Herstellung. |
US5183690A (en) * | 1990-06-25 | 1993-02-02 | The United States Of America, As Represented By The Secretary Of Agriculture | Starch encapsulation of biologically active agents by a continuous process |
GB9014646D0 (en) | 1990-07-02 | 1990-08-22 | Courtaulds Coatings Holdings | Coating compositions |
US5194262A (en) * | 1990-10-22 | 1993-03-16 | Revlon Consumer Products Corporation | Encapsulated antiperspirant salts and deodorant/antiperspirants |
US5196199A (en) * | 1990-12-14 | 1993-03-23 | Fuisz Technologies Ltd. | Hydrophilic form of perfluoro compounds and method of manufacture |
US5292657A (en) * | 1990-12-31 | 1994-03-08 | Pioneer Hi-Bred International, Inc. | Process for preparing rotary disc fatty acid microspheres of microorganisms |
US5143662A (en) * | 1991-02-12 | 1992-09-01 | United States Surgical Corporation | Process for preparing particles of bioabsorbable polymer |
US5707546A (en) * | 1991-06-17 | 1998-01-13 | Rio Linda Chemical Co., Inc. | Generation and storage of chlorine dioxide in a non-aqueous medium |
US5405617A (en) * | 1991-11-07 | 1995-04-11 | Mcneil-Ppc, Inc. | Aliphatic or fatty acid esters as a solventless carrier for pharmaceuticals |
GB9201857D0 (en) * | 1992-01-29 | 1992-03-18 | Smithkline Beecham Plc | Novel compound |
JP3265680B2 (ja) * | 1992-03-12 | 2002-03-11 | 大正製薬株式会社 | 経口製剤用組成物 |
DE4214272A1 (de) * | 1992-05-04 | 1993-11-11 | Nukem Gmbh | Verfahren und Vorrichtung zur Herstellung von Mikrokugeln |
CA2095776C (en) * | 1992-05-12 | 2007-07-10 | Richard C. Fuisz | Rapidly dispersable compositions containing polydextrose |
EP0641195B1 (de) * | 1992-05-22 | 1996-04-10 | Gödecke Aktiengesellschaft | Verfahren zur herstellung retardierter arzneimittelzubereitungen |
US5518730A (en) * | 1992-06-03 | 1996-05-21 | Fuisz Technologies Ltd. | Biodegradable controlled release flash flow melt-spun delivery system |
TW271400B (es) * | 1992-07-30 | 1996-03-01 | Pfizer | |
US5348758A (en) * | 1992-10-20 | 1994-09-20 | Fuisz Technologies Ltd. | Controlled melting point matrix formed with admixtures of a shearform matrix material and an oleaginous material |
US5380473A (en) * | 1992-10-23 | 1995-01-10 | Fuisz Technologies Ltd. | Process for making shearform matrix |
GB9224855D0 (en) * | 1992-11-27 | 1993-01-13 | Smithkline Beecham Plc | Pharmaceutical compositions |
US5569467A (en) | 1993-05-15 | 1996-10-29 | Societe De Conseils De Recherches Et D'applications (S.C.R.A.S.) | Process for the preparation of microballs and microballs thus obtained |
US5690959A (en) | 1993-05-29 | 1997-11-25 | Smithkline Beecham Corporation | Pharmaceutical thermal infusion process |
US5851553A (en) | 1993-09-10 | 1998-12-22 | Fuisz Technologies, Ltd. | Process and apparatus for making rapidly dissolving dosage units and product therefrom |
US5935600A (en) * | 1993-09-10 | 1999-08-10 | Fuisz Technologies Ltd. | Process for forming chewable quickly dispersing comestible unit and product therefrom |
US5597416A (en) * | 1993-10-07 | 1997-01-28 | Fuisz Technologies Ltd. | Method of making crystalline sugar and products resulting therefrom |
US5433951A (en) * | 1993-10-13 | 1995-07-18 | Bristol-Myers Squibb Company | Sustained release formulation containing captopril and method |
AT401871B (de) * | 1994-01-28 | 1996-12-27 | Gebro Broschek Gmbh | Verfahren zur herstellung von s(+)-ibuprofen- partikeln mit verbesserten fliesseigenschaften und deren verwendung zur arzneimittelherstellung |
GB9402203D0 (en) * | 1994-02-04 | 1994-03-30 | Smithkline Beecham Plc | Pharmaceutical formulation |
DE69535127T2 (de) * | 1994-03-18 | 2007-02-15 | Supernus Pharmaceuticals, Inc. | Emulgierte arzneistoffabgabesysteme |
US5605889A (en) * | 1994-04-29 | 1997-02-25 | Pfizer Inc. | Method of administering azithromycin |
PL179910B1 (pl) * | 1994-05-06 | 2000-11-30 | Pfizer | Postac dawkowania o kontrolowanym uwalnianiu zawierajaca azytromycyne PL PL PL PL PL PL PL PL |
DE19509807A1 (de) * | 1995-03-21 | 1996-09-26 | Basf Ag | Verfahren zur Herstellung von Wirkstoffzubereitungen in Form einer festen Lösung des Wirkstoffs in einer Polymermatrix sowie mit diesem Verfahren hergestellte Wirkstoffzubereitungen |
US5567439A (en) * | 1994-06-14 | 1996-10-22 | Fuisz Technologies Ltd. | Delivery of controlled-release systems(s) |
US5582855A (en) | 1994-07-01 | 1996-12-10 | Fuisz Technologies Ltd. | Flash flow formed solloid delivery systems |
US5556652A (en) * | 1994-08-05 | 1996-09-17 | Fuisz Technologies Ltd. | Comestibles containing stabilized highly odorous flavor component delivery systems |
US5601761A (en) * | 1994-09-26 | 1997-02-11 | The Dow Chemical Company | Encapsulated active materials and method for preparing same |
US5493044A (en) * | 1994-10-20 | 1996-02-20 | Fmc Corporation | Process for preparing alkylsilyl or arylsilyl ethers |
US5965164A (en) | 1994-10-28 | 1999-10-12 | Fuisz Technologies Ltd. | Recipient-dosage delivery system |
US5683720A (en) | 1994-10-28 | 1997-11-04 | Fuisz Technologies Ltd. | Liquiflash particles and method of making same |
US6083430A (en) * | 1994-10-28 | 2000-07-04 | Fuisz Technologies Ltd. | Method of preparing a dosage unit by direct tableting and product therefrom |
US5965161A (en) * | 1994-11-04 | 1999-10-12 | Euro-Celtique, S.A. | Extruded multi-particulates |
FR2732621B1 (fr) * | 1995-04-10 | 1997-06-06 | Rhone Poulenc Chimie | Perles d'un produit presentant le phenomene de surfusion et leur procede d'obtention |
ES2279519T3 (es) | 1995-05-02 | 2007-08-16 | Taisho Pharmaceutical Co. Ltd | Composicion para administracion por via oral. |
US5883103A (en) * | 1995-06-07 | 1999-03-16 | Shire Laboratories Inc. | Oral acyclovir delivery |
US5747058A (en) * | 1995-06-07 | 1998-05-05 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system |
AU6403196A (en) * | 1995-06-30 | 1997-02-05 | Baylor University | Polyester/carboxylic acid composite materials |
EP0784933A3 (en) * | 1995-10-16 | 1997-11-26 | Leaf, Inc. | Extended release of additives in comestible products |
US5919489A (en) * | 1995-11-01 | 1999-07-06 | Abbott Laboratories | Process for aqueous granulation of clarithromycin |
US5705190A (en) * | 1995-12-19 | 1998-01-06 | Abbott Laboratories | Controlled release formulation for poorly soluble basic drugs |
US5916582A (en) * | 1996-07-03 | 1999-06-29 | Alza Corporation | Aqueous formulations of peptides |
DE19629753A1 (de) * | 1996-07-23 | 1998-01-29 | Basf Ag | Verfahren zur Herstellung von festen Arzneiformen |
US6139872A (en) | 1996-08-14 | 2000-10-31 | Henkel Corporation | Method of producing a vitamin product |
HRP970485A2 (en) * | 1996-09-13 | 1998-08-31 | Joerg Rosenberg | Process for producing solid pharmaceutical forms |
US8828432B2 (en) * | 1996-10-28 | 2014-09-09 | General Mills, Inc. | Embedding and encapsulation of sensitive components into a matrix to obtain discrete controlled release particles |
DE19652257A1 (de) * | 1996-12-16 | 1998-06-18 | Lohmann Therapie Syst Lts | Einzeln dosierte, bei Kontakt mit Flüssigkeit schnell zerfallende, wirkstoff- und insbesondere aromastoffhaltige, folienförmige Darreichnungsform |
US5948407A (en) * | 1997-03-19 | 1999-09-07 | Shire Laboratories Inc. | Oral induction of tolerance to parenterally administered non-autologous polypeptides |
US6551616B1 (en) * | 1997-04-11 | 2003-04-22 | Abbott Laboratories | Extended release formulations of erythromycin derivatives |
US6010718A (en) * | 1997-04-11 | 2000-01-04 | Abbott Laboratories | Extended release formulations of erythromycin derivatives |
US6656508B2 (en) * | 1997-04-17 | 2003-12-02 | Amgen Inc. | Sustained-release alginate gels |
DE19729487A1 (de) * | 1997-07-10 | 1999-01-14 | Dresden Arzneimittel | Verfahren zur Herstellung von Wirkstoff-Zubereitungen mit kontrollierter Freisetzung aus einer Matrix |
SI9700186B (sl) * | 1997-07-14 | 2006-10-31 | Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. | Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin |
US5851555A (en) | 1997-08-15 | 1998-12-22 | Fuisz Technologies Ltd. | Controlled release dosage forms containing water soluble drugs |
US5869098A (en) * | 1997-08-20 | 1999-02-09 | Fuisz Technologies Ltd. | Fast-dissolving comestible units formed under high-speed/high-pressure conditions |
US5840334A (en) | 1997-08-20 | 1998-11-24 | Fuisz Technologies Ltd. | Self-binding shearform compositions |
US5980941A (en) | 1997-08-20 | 1999-11-09 | Fuisz Technologies Ltd. | Self-binding shearform compositions |
IT1294760B1 (it) * | 1997-09-03 | 1999-04-12 | Jagotec Ag | Procedimento per la preparazione di compresse farmaceutiche in grado di cedere,secondo schemi predeterminabili, principi attivi poco |
US6692767B2 (en) * | 1997-09-19 | 2004-02-17 | Shire Laboratories Inc. | Solid solution beadlet |
US6013280A (en) * | 1997-10-07 | 2000-01-11 | Fuisz Technologies Ltd. | Immediate release dosage forms containing microspheres |
IE970731A1 (en) * | 1997-10-07 | 2000-10-04 | Fuisz Internat Ltd | Product and method for the treatment of hyperlipidemia |
US6096340A (en) * | 1997-11-14 | 2000-08-01 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
US5891845A (en) * | 1997-11-21 | 1999-04-06 | Fuisz Technologies Ltd. | Drug delivery systems utilizing liquid crystal structures |
US6328993B1 (en) * | 1997-12-08 | 2001-12-11 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Oral administration form for an acid liable active proton pump inhibitor |
US6270804B1 (en) * | 1998-04-03 | 2001-08-07 | Biovail Technologies Ltd. | Sachet formulations |
US6423345B2 (en) * | 1998-04-30 | 2002-07-23 | Acusphere, Inc. | Matrices formed of polymer and hydrophobic compounds for use in drug delivery |
JPH11335300A (ja) * | 1998-05-20 | 1999-12-07 | Sumitomo Pharmaceut Co Ltd | グリセリン脂肪酸エステルを使用した徐放性製剤 |
FR2779651B1 (fr) * | 1998-06-16 | 2001-04-20 | Gattefosse Ets Sa | Procede pour la fabrication de comprimes a liberation prolongee de principe(s) actif(s) presentant une cinetique de dissolution d'ordre zero |
US6117452A (en) * | 1998-08-12 | 2000-09-12 | Fuisz Technologies Ltd. | Fatty ester combinations |
US6086920A (en) * | 1998-08-12 | 2000-07-11 | Fuisz Technologies Ltd. | Disintegratable microspheres |
CA2245398C (en) * | 1998-08-21 | 2002-01-29 | Apotex Inc. | Azithromycin monohydrate isopropanol clathrate and methods for the manufacture thereof |
US6165512A (en) | 1998-10-30 | 2000-12-26 | Fuisz Technologies Ltd. | Dosage forms containing taste masked active agents |
EP1152765B1 (en) * | 1998-11-30 | 2004-10-13 | Teva Pharmaceutical Industries Ltd. | Ethanolate of azithromycin, process for manufacture, and pharmaceutical compositions thereof |
DE19901683B4 (de) * | 1999-01-18 | 2005-07-21 | Grünenthal GmbH | Analgetikum mit kontrollierter Wirkstofffreisetzung |
DE60042352D1 (de) * | 1999-02-10 | 2009-07-23 | Pfizer Prod Inc | Osmotisches System zur Verabreichung von Wirkstoffen, die feste amorphe Dispersionen enthalten |
US6706283B1 (en) * | 1999-02-10 | 2004-03-16 | Pfizer Inc | Controlled release by extrusion of solid amorphous dispersions of drugs |
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US6291013B1 (en) * | 1999-05-03 | 2001-09-18 | Southern Biosystems, Inc. | Emulsion-based processes for making microparticles |
US6395300B1 (en) * | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
WO2001022937A1 (en) * | 1999-09-27 | 2001-04-05 | Sonus Pharmaceuticals, Inc. | Compositions of tocol-soluble therapeutics |
IL141438A0 (en) * | 2000-02-23 | 2002-03-10 | Pfizer Prod Inc | Method of increasing the bioavailability and tissue penetration of azithromycin |
AR030557A1 (es) * | 2000-04-14 | 2003-08-27 | Jagotec Ag | Una tableta en multicapa de liberacion controlada y metodo de tratamiento |
IL161259A0 (en) * | 2001-12-21 | 2004-09-27 | Pfizer Prod Inc | Methods for wet granulating azithromycin |
MXPA04005105A (es) * | 2001-12-21 | 2004-08-19 | Pfizer Prod Inc | Formulaciones de acitromicina directamente compresibles. |
US6682759B2 (en) * | 2002-02-01 | 2004-01-27 | Depomed, Inc. | Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs |
AU2003201146B2 (en) * | 2002-02-01 | 2008-04-17 | Pfizer Products Inc. | Dry granulated formulations of azithromycin |
US20040121003A1 (en) * | 2002-12-19 | 2004-06-24 | Acusphere, Inc. | Methods for making pharmaceutical formulations comprising deagglomerated microparticles |
WO2005009447A1 (en) * | 2003-07-24 | 2005-02-03 | Pliva - Research And Development Ltd. | Single dose fast dissolving azithromycin |
-
2004
- 2004-01-23 US US10/763,340 patent/US6984403B2/en not_active Expired - Lifetime
- 2004-05-06 ES ES04252643T patent/ES2312929T3/es not_active Expired - Lifetime
- 2004-05-06 DK DK04252643T patent/DK1537859T3/da active
- 2004-05-06 PT PT04252643T patent/PT1537859E/pt unknown
- 2004-05-06 AT AT04252643T patent/ATE407663T1/de active
- 2004-05-06 SI SI200430865T patent/SI1537859T1/sl unknown
- 2004-05-06 DE DE602004016444T patent/DE602004016444D1/de not_active Expired - Lifetime
- 2004-05-06 EP EP04252643A patent/EP1537859B1/en not_active Expired - Lifetime
- 2004-05-06 PL PL04252643T patent/PL1537859T3/pl unknown
- 2004-05-14 NZ NZ535464A patent/NZ535464A/en unknown
- 2004-05-14 RS YUP-847/04A patent/RS84704A/sr unknown
- 2004-05-14 WO PCT/IB2004/001654 patent/WO2005053650A1/en active Application Filing
- 2004-05-14 PL PL379984A patent/PL379984A1/pl not_active Application Discontinuation
- 2004-05-14 MX MXPA04009424A patent/MXPA04009424A/es active IP Right Grant
- 2004-05-14 EA EA200401216A patent/EA010110B1/ru not_active IP Right Cessation
- 2004-05-14 GE GEAP8414A patent/GEP20074056B/en unknown
- 2004-05-14 OA OA1200400253A patent/OA12858A/en unknown
- 2004-05-14 BR BRPI0403935A patent/BRPI0403935B8/pt active IP Right Grant
- 2004-05-18 CA CA2467611A patent/CA2467611C/en not_active Expired - Lifetime
- 2004-06-02 NL NL1026315A patent/NL1026315C2/nl not_active IP Right Cessation
- 2004-06-04 TW TW093116207A patent/TWI351969B/zh active
- 2004-06-16 CL CL200401501A patent/CL2004001501A1/es unknown
- 2004-08-04 JP JP2004228455A patent/JP4602711B2/ja active Active
- 2004-09-07 PE PE2004000861A patent/PE20050573A1/es not_active Application Discontinuation
- 2004-09-08 PA PA20048611501A patent/PA8611501A1/es unknown
- 2004-09-09 DO DO2004P000994A patent/DOP2004000994A/es unknown
- 2004-09-10 AR ARP040103256A patent/AR045630A1/es not_active Application Discontinuation
- 2004-09-13 UY UY28509A patent/UY28509A1/es not_active Application Discontinuation
- 2004-09-17 NO NO20043903A patent/NO20043903L/no not_active Application Discontinuation
- 2004-09-20 IS IS7464A patent/IS2672B/is unknown
- 2004-09-20 HR HR20040865A patent/HRP20040865A2/hr not_active Application Discontinuation
- 2004-09-20 IL IL164165A patent/IL164165A/en active IP Right Grant
- 2004-09-29 CR CR7500A patent/CR7500A/es unknown
- 2004-10-11 KR KR1020047016213A patent/KR100906290B1/ko active IP Right Grant
-
2005
- 2005-08-25 US US11/212,433 patent/US20060029677A1/en not_active Abandoned
- 2005-10-26 US US11/259,839 patent/US20060039988A1/en not_active Abandoned
- 2005-12-08 MA MA28638A patent/MA27848A1/fr unknown
-
2006
- 2006-01-05 HK HK06100226.0A patent/HK1080367B/zh not_active IP Right Cessation
-
2007
- 2007-07-18 US US11/779,489 patent/US20080015343A1/en not_active Abandoned
-
2008
- 2008-11-06 CY CY20081101264T patent/CY1108486T1/el unknown
-
2010
- 2010-03-01 JP JP2010044743A patent/JP2010132700A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DOP2004000994A (es) | Derivados de indano heterociclicos sustituidos y compuestos relacionados para el tratamiento de la esquizofrenia. | |
RU2011117203A (ru) | Системное лечение кровососущих паразитов и паразитов-консументов крови посредством перорального введения антипаразитного средства | |
AR048431A1 (es) | Formulaciones galenicas de compuestos organicos | |
MX2007006212A (es) | Medicamento oral para liberacion modificada de al menos un principio activo bajo forma multimicrocapsular. | |
UY27533A1 (es) | Composiciones farmacéuticas que contienen oxibutinina | |
PE20160195A1 (es) | Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington | |
ES2088312T3 (es) | Formulacion de liberacion controlada que contiene tramadol. | |
ECSP099350A (es) | COMPUESTOS DE TETRAHIDROCICLOPENTA[b]INDOL COMO MODULADORES | |
CR9662A (es) | Ingrediente farmaceutico canabinoide activo para formas de dosis mejoradas | |
ES2570401T3 (es) | Métodos de tratamiento usando dosis únicas de oritavancina | |
WO2009026473A3 (en) | Stabilized therapeutic compositions and formulations | |
RU2008119454A (ru) | Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом | |
PA8616201A1 (es) | Composiciones farmaceuticas de liberacion sostenida | |
WO2007038428A3 (en) | Prevention and treatment of gastrointestinal and bladder disorders using active vitamin d compounds | |
BR0311414A (pt) | Agente terapêutico para uma bexiga hiperativa | |
AR047469A1 (es) | Conservantes antimicrobianos para lograr una formulacion de dosis multiples usando ciclodextrinas beta para formas de dosificacion liquidas | |
ECSP045351A (es) | Formas de dosificación de azitromicina con efectos secundarios reducidos | |
PT1656131E (pt) | Utilização de betaína para tratar claudicação intermitente | |
PE20040706A1 (es) | Derivado especifico de amina ciclica y sus sales farmaceuticamente aceptables involucrados en la prevencion de la insuficiencia cardiaca | |
ES2182504T3 (es) | Bifenilsulfonilcianamidas, procedimiento para su preparacion y su utilizacion como medicamento. | |
UY26459A1 (es) | 3,4-dihidroquinazolinas 5,6-disustituidas | |
AR036009A1 (es) | Composicion farmaceutica para el tratamiento o prevencion del dolor visceral y los trastornos gastrointestinales que comprenden un compuesto aminoácido biciclico y uso de este ultimo para fabricar dicha composicion farmaceutica | |
PA8483301A1 (es) | Concentrado oral de sertralina | |
AR037543A1 (es) | Metodo para la terapia del cancer y composicion farmaceutica | |
KR920700626A (ko) | 톡소플라스마병의 치료용 약제 |